Neuroblastoma
📧 Sign up to get email alerts when something new happens for Neuroblastoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
This clinical trial aims to perform a comprehensive molecular analysis of endocrine neoplasms and is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma [Phase 1]
This is a Phase 1 clinical trial evaluating a multi-modular CAR-T therapy targeting GD2 for neuroblastoma. The study is active but not curre…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma [Phase 3]
A Phase 3 trial is recruiting to test dinutuximab plus chemotherapy, surgery, and stem cell transplantation for newly diagnosed high-risk ne…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
A National Cancer Institute–sponsored clinical trial is conducting comprehensive omics analyses of pediatric and adult solid tumors and esta…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Construction and Validation of an Intelligent Ultrasound Diagnostic System for the Spectrum of Neuroblastoma in Children
Development and validation of an intelligent ultrasound diagnostic system for the spectrum of neuroblastoma in children.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients [Phase 2, Phase 3]
A Phase 2/Phase 3 safety and efficacy study of hu14 for high-risk neuroblastoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Familial Investigations of Childhood Cancer Predisposition
An ongoing St. Jude-led clinical trial is investigating familial cancer predisposition syndromes in children and is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
A clinical trial sponsored by St. Jude is evaluating the feasibility of screening for early late effects in survivors of high-risk neuroblas…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma [Phase 1]
Phase 1 clinical trial update for iC9-GD2-CAR-VZV-CTLs in GD2-positive osteosarcoma and neuroblastoma; the study is currently active but not…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5 [Phase 2]
A phase 2 trial will add naxitamab and GM-CSF to the standard COG-type induction therapy for newly diagnosed high-risk neuroblastoma in pati…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma [Phase 1]
An ongoing Phase I trial is evaluating a combination of rhIL-15, dinutuximab, irinotecan, and temozolomide in children and young adults with…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse [Phase 1, Phase 2]
Clinical trial update describing the addition of iberdomide to therapy for neuroblastoma that has recurred or is refractory, in Phase 1/2 an…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors [Phase 1, Phase 2]
This clinical trial update indicates that the PEEL-224 study of vincristine and temozolomide for pediatric refractory or relapsed solid tumo…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) [Phase 1]
Phase 1 clinical trial update for a B7-H3–targeted autologous CAR-T cell therapy (3CAR) in pediatric solid tumors, currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies [Phase 1]
Phase 1 trial at New York Medical College evaluating vorinostat in combination with chemotherapy for relapsed/refractory solid tumors and CN…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Lutathera (177Lu-DOTATATE) in combination with Olaparib for somatostatin receptor–expressing recurrent…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas [Phase 1, Phase 2]
Clinical trial update reports ongoing Phase 1/Phase 2 testing of eflornithine (DFMO) with AMXT 1501 for neuroblastoma, CNS tumors, and sarco…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Clinical trial update notes an expanded access protocol for 131I-MIBG therapy in refractory neuroblastoma, with conditions including childho…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) [Phase 2]
This update reports on a Phase 2 pediatric MATCH trial evaluating ensartinib for patients with relapsed or refractory ALK- or ROS1-genomic a…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma [Phase 1]
Phase 1 clinical trial investigating lenalidomide and dinutuximab with or without isotretinoin in younger patients with refractory or recurr…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors [Phase 1, Phase 2]
Clinical trial evaluating silmitasertib (CX-4945) in combination with chemotherapy for relapsed or refractory solid tumors; Phase 1 and Phas…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
This clinical trial update reports on using serial ctDNA and molecular residual disease monitoring to assess disease burden in neuroblastoma…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Open-Label Study of 18F-mFBG for Imaging Neuroblastoma [Phase 3]
Open-label Phase 3 clinical trial evaluating 18F-mFBG imaging for neuroblastoma; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma [Phase 2]
Phase 2 clinical trial update for a neuroblastoma vaccine combined with beta-glucan; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma [Phase 2]
A Phase 2 clinical trial evaluating iodine-131 labeled metaiodobenzylguanidine (MIBG) in patients with recurrent or refractory neuroblastoma…